Andrea Charles | 11/06/2012
In this interview Kenneth J. Olivier Jr., PhD, Director of Toxicology at Merrimack Pharmaceuticals, speaks to Andrea Charles from Pharma IQ, about what trends he is witnessing in the improvement of safety assessments, his top 3 preclinical considerations in the discovery and development of novel oncology therapeutics and the implications and future considerations for use of computational biology in clinical drug development.
Have...
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
DigIT Pharma & Health 2024
September 10 - 12, 2024
Düsseldorf, Germany
Register Now |
View Agenda |
Learn More
Temperature Control and Logistics North America Summit
September 10 - 12, 2024
Falls Church, VA
Register Now |
View Agenda |
Learn More